This is a specific kind of leukemia that affects T-cells, which are a type of white blood cell. It's a cancer where these T-cells multiply too quickly and don't die off when they should.
Every report comes from a Lived member, sent anonymously.
Have you had Stem Cell Transplant for T-Cell Leukemia?
T-cell leukemia is not one disease but a group of blood cancers that start in T cells, the white blood cells that direct and carry out much of the immune system's response. In each type, abnormal T cells multiply and build up in the blood, bone marrow, spleen, lymph nodes or skin. They can crowd out healthy blood cells, which leads to tiredness, infections or easy bruising, and some types also enlarge organs or cause skin changes. The types behave so differently that knowing which one a person has matters more than the umbrella name. T-cell acute lymphoblastic leukemia (T-ALL) is a fast-growing cancer of immature T cells, seen mostly in children, teenagers and young adults, and it needs treatment right away. T-cell large granular lymphocytic leukemia (T-LGL) is usually slow-growing, tends to appear in people in their 60s, and causes problems mainly by lowering blood counts. T-cell prolymphocytic leukemia (T-PLL) is a rare and usually aggressive disease of older adults. Adult T-cell leukemia/lymphoma (ATL) is caused by a virus called human T-lymphotropic virus type 1 (HTLV-1) and ranges from slow to very fast forms. Sézary syndrome, the leukemic form of a lymphoma that starts in the skin, is related but is usually grouped with lymphomas.
Like other leukemias, T-cell leukemias begin with changes in the genetic material (DNA) of a developing blood cell that let it grow and survive when it should not. In most people, nothing they did caused these changes, and why they happened is not known. Some risk factors belong to one type only. ATL is the clearest example: it is caused by long-term infection with HTLV-1, which is common in southwestern Japan, Central and South America, parts of Africa, the Middle East and some other regions. The virus spreads mainly through breastfeeding, sex, shared needles and blood transfusion, and infection early in life through breast milk appears to matter most. Even so, only a few percent of people who carry HTLV-1 from birth go on to develop ATL, typically many years later. T-ALL is more common in boys and men than in girls and women, and, as with other forms of acute lymphoblastic leukemia, earlier chemotherapy or radiation can raise the risk. T-LGL often occurs alongside autoimmune conditions and is thought to grow out of T cells that keep reacting to a long-running immune trigger, although no single trigger has been identified.
Diagnosis usually begins with a complete blood count (CBC), which measures red cells, white cells and platelets. A high white cell count, a low count of neutrophils (the white cells that fight bacteria), anemia or low platelets can all prompt a closer look. A specialist then examines the cells under a microscope and uses flow cytometry, a test that reads the protein markers on each cell's surface, to show that the abnormal cells are T cells and which kind they are. Genetic tests on the cells can confirm that they all come from a single abnormal cell and can find changes that help guide treatment. A bone marrow biopsy, in which a small sample is taken from the hip bone with a needle, shows how much of the marrow is involved and is routine for T-ALL. Scans may look for enlarged lymph nodes, an enlarged spleen or, in T-ALL, a mass in the chest. For ATL, a blood test for HTLV-1 antibodies is part of the diagnosis, and blood calcium and lactate dehydrogenase (LDH, an enzyme that rises when cells are growing and breaking down quickly) help sort it into one of its four subtypes. T-LGL is often found when routine blood tests keep showing low neutrophils in someone who otherwise feels fairly well.
Treatment depends almost entirely on the type and how active it is. T-ALL is treated promptly with combination chemotherapy given in phases: an intensive first phase aimed at remission (no detectable leukemia), followed by further phases to destroy remaining cells and keep the leukemia from returning. Treatment also protects the brain and spinal cord, where leukemia cells can hide, usually with chemotherapy injected into the spinal fluid. Teenagers and young adults often do better on regimens modeled on those used for children. If the leukemia does not respond or comes back after at least two earlier regimens, nelarabine (Arranon), a chemotherapy drug approved specifically for T-cell disease, is one option, and a stem cell transplant from a donor may be offered to people at high risk of relapse. T-LGL often needs no treatment at diagnosis, only regular blood tests. About half of people eventually need treatment, usually because of severe neutropenia, repeated infections or anemia that requires transfusions. The usual medicines are immune-suppressing drugs such as methotrexate, cyclophosphamide or cyclosporine, which improve blood counts in roughly 6 of 10 people treated. Active T-PLL is usually treated with alemtuzumab, an antibody given by infusion that attaches to a protein on the leukemia cells and destroys them. It often works well at first, but responses usually do not last, so people who are fit enough are referred for a donor stem cell transplant, which offers the best chance of long-term control. Alemtuzumab weakens the immune system considerably, so infections, including reactivation of cytomegalovirus (a common virus that can lie dormant in the body), are watched for closely. ATL treatment is matched to its subtype. Slow-growing smoldering and favorable chronic forms may be watched without treatment until they progress. In many countries, an antiviral combination of zidovudine (a medicine also used for HIV) and interferon alpha is used for the acute, chronic and smoldering forms, while the lymphoma form is treated with chemotherapy. For aggressive ATL, a donor stem cell transplant is considered for suitable people, and in Japan newer drugs such as the antibody mogamulizumab are also approved. Because the mature T-cell leukemias are rare and evidence is limited, clinical trials are an important option.
The outlook depends heavily on the type. With modern chemotherapy, more than 80% of children, teenagers and young adults with T-ALL are cured. Treatment is demanding, with stretches when infection risk is high, and results are less favorable in older adults and when leukemia comes back: fewer than 7 in 10 adults with T-ALL achieve long-term survival. T-LGL is usually a long-term condition that people live with for years. Daily life is shaped mostly by blood counts. The main danger is infection when neutrophils are low, and some people need regular transfusions for anemia. Blood tests continue indefinitely, and treatment may be started, paused or changed over time. T-PLL and the acute and lymphoma forms of ATL are serious diseases that often return after treatment, so planning for a possible transplant, infection prevention and practical support usually starts early. Some people with T-PLL or with smoldering or chronic ATL have a quieter phase before the disease becomes active, which makes regular monitoring important. Because these leukemias are rare, care from, or a second opinion at, a center experienced in T-cell cancers is often worthwhile.
See a clinician if you have ongoing tiredness, frequent or unusual infections, easy bruising or bleeding, drenching night sweats, unexplained weight loss, swollen lymph nodes, or a skin rash or lumps that do not go away. Low white cell counts that keep showing up on routine blood tests are also worth a specialist's review. During treatment, or if you have been told your neutrophil count is low, call your care team right away for a fever of 100.5°F (38°C) or higher, chills, or redness and swelling where a catheter enters the skin. In this setting, infection can become life threatening and needs urgent attention.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with T-Cell Leukemia is like, what's helped you, or ask the community a question.